Natalizumab and HSV meningitis

Erica Seiguer Shenoy; Eleftherios Mylonakis; Rocio M. Hurtado; Nagagopal Venna

doi:10.1007/s13365-011-0027-4

Natalizumab and HSV meningitis

Erica Seiguer Shenoy, Eleftherios Mylonakis, Rocio M. Hurtado, Nagagopal Venna

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

Original language	English (US)
Pages (from-to)	288-290
Number of pages	3
Journal	Journal of NeuroVirology
Volume	17
Issue number	3
DOIs	https://doi.org/10.1007/s13365-011-0027-4
State	Published - Jun 2011

ASJC Scopus subject areas

Neurology
Clinical Neurology
Cellular and Molecular Neuroscience
Virology

Access to Document

10.1007/s13365-011-0027-4

Cite this

@article{fcbb4694a19d4efebf878f7aee161c00,

title = "Natalizumab and HSV meningitis",

abstract = "Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.",

author = "Shenoy, {Erica Seiguer} and Eleftherios Mylonakis and Hurtado, {Rocio M.} and Nagagopal Venna",

year = "2011",

month = jun,

doi = "10.1007/s13365-011-0027-4",

language = "English (US)",

volume = "17",

pages = "288--290",

journal = "Journal of NeuroVirology",

issn = "1355-0284",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - Natalizumab and HSV meningitis

AU - Shenoy, Erica Seiguer

AU - Mylonakis, Eleftherios

AU - Hurtado, Rocio M.

AU - Venna, Nagagopal

PY - 2011/6

Y1 - 2011/6

N2 - Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

AB - Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

UR - http://www.scopus.com/inward/record.url?scp=79959985339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959985339&partnerID=8YFLogxK

U2 - 10.1007/s13365-011-0027-4

DO - 10.1007/s13365-011-0027-4

M3 - Article

C2 - 21487835

AN - SCOPUS:79959985339

VL - 17

SP - 288

EP - 290

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 3

ER -

Natalizumab and HSV meningitis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this